You are here: Home > For Researchers > Projects > IOTA 3 Ovarian tumour characterisation - Multicentre prospective assessment study on the pre-operative characterisation of ovarian tumours based on predictive computer models

IOTA 3 Ovarian tumour characterisation - Multicentre prospective assessment study on the pre-operative characterisation of ovarian tumours based on predictive computer models

From 01-06-2008 to 31-05-2012

Description

The aim is to prospectively test and implement previously developed mathematical algorithms for the pre-operative classification of adnexal masses. IOTA phase 3 is a prospective multicentre study. The information obtained will be used to define the optimal management of patients presenting with adnexal tumours. More than 2,000 patients, with at least one adnexal mass, will be recruited and studied within 3 months before investigative surgery. Medical and family histories will be recorded. Transvaginal ultrasonography with colour Doppler imaging will be used to derive indices of tumour form and blood flow. A sample of peripheral venous blood will be taken for the analyses of serum CA-125 and other tumour markers and in certain centres additional blood will be taken and stored appropriately to test proteomic pattern analysis. Findings at surgery and the histological classification of excised tissues as malignant or benign (and by cell type) will be used as outcome measures. Conventional and novel algorithms (including proteomic patterns), which can be used to effectively classify difficult adnexal masses will be tested prospectively in centres throughout the world.
Dirk Timmerman (spokesperson)

Team

Financing

Funding: IWT - Agentschap voor Innovatie door Wetenschap en Technologie 

Program/Grant Type: IWT TBM - VLAIO TBM Projects Applied Biomedical Research with a Primary Social finality

Events

2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery


3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery


12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers


More events

News

STADIUS Alumni Herman Verrelst – new CEO of Biocartis

08 June 2017

Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.


Supporting healthcare policymaking via machine learning – batteries included!

29 May 2017

STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.


Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"

10 February 2017

Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?


Joos Vandewalle is nieuwe voorzitter KVAB

09 October 2016

Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.


More news

Logo STADIUS